PRECIGEN, INC. Deferred Revenue
PRECIGEN, INC. (PGEN) had Deferred Revenue of $39.82 million as of 2018-06-30, per its 10-Q filed 2018-08-13.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2018-08-13
- 2018-06-30: Deferred Revenue, Current $39.82M.
- 2018-03-31: Deferred Revenue, Current $38.38M; Deferred Revenue, Current as first filed $48.65M.
- 2017-12-31: Deferred Revenue, Current $42.87M.
- 2017-09-30: Deferred Revenue, Current $48.29M.
| Period end | Deferred Revenue, Current | Deferred Revenue, Current as first filed |
|---|---|---|
| 2018-06-30 | $39.82M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $38.38M 10-Q/A · filed 2018-08-13 | $48.65M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $42.87M 10-Q/A · filed 2018-08-13 | |
| 2017-09-30 | $48.29M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $47.66M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $50.33M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $53.36M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $54.94M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $53.86M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $37.70M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $35.37M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $32.01M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $28.74M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $17.29M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $16.52M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $13.95M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $10.71M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $10.94M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $7.79M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $7.40M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $8.27M 10-Q/A · filed 2013-10-21 | |
| 2012-12-31 | $9.96M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |